Viewing Study NCT02970318


Ignite Creation Date: 2025-12-25 @ 5:02 AM
Ignite Modification Date: 2026-02-25 @ 7:08 PM
Study NCT ID: NCT02970318
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-10-27
First Post: 2016-11-18
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Sponsor: Acerta Pharma BV
Organization: